View:
Download DOC
Download PDF
Download XLS
SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 		 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Bellon Steven F.
(Last) (First) (Middle)
500 TECHNOLOGY SQUARE, STE 700
(Street)
CAMBRIDGE MA 02139
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/22/2020 		3. Issuer Name and Ticker or Trading Symbol
Foghorn Therapeutics Inc. [ FHTX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 128,378 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) (1) 01/30/2029 Common Stock 4,053 0.73 D
Stock Option (Right to Buy) (2) 02/13/2029 Common Stock 29,729 3.72 D
Stock Option (Right to Buy) (3) 08/18/2030 Common Stock 43,243 8.77 D
Stock Option (Right to Buy) (4) 08/20/2030 Common Stock 64,864 8.77 D
Explanation of Responses:
1. The option vested at a rate of 6.25% of the underlying shares beginning on April 1, 2018 and thereafter on the first day of each calendar quarter until the option is fully vested.
2. The option vested as to 25% of the underlying shares of common stock on January 30, 2020, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested.
3. The option shall vest as to 25% of the underlying shares of common stock on August 17, 2021, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested.
4. The option shall vest as to 25% of the underlying shares of common stock on August 17, 2021, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested.
Remarks:
Senior Vice President, Drug Discovery Exhibit List: Exhibit 24 - Power of Attorney
By: /s/ Allan Reine, M.D., Attorney-in-Fact 11/13/2020
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
                           LIMITED POWER OF ATTORNEY

     The undersigned hereby constitutes and appoints Allan Reine and Tara
Maduri, and each of them individually, with full power of substitution,
as the undersigned's true and lawful attorney-in-fact to:

     (1)     prepare, execute in the undersigned's name and on the undersigned's
             behalf, and submit to the U.S. Securities and Exchange Commission
             (the "SEC") a Form ID, including amendments thereto, and any other
             documents necessary or appropriate to obtain codes and passwords
             enabling the undersigned to make electronic filings with the SEC of
             reports required by Section 16(a) of the Securities Exchange Act of
             1934, as amended, or any rule or regulation of the SEC;

     (2)     execute for and on behalf of the undersigned, in the undersigned's
             capacity as officer and/or director of Foghorn Therapeutics Inc.
             (the "Company"), Forms 3, 4, 5 and any Schedules 13D or 13G in
             accordance with Section 16(a) of the Securities Exchange Act of
             1934, as amended, and the rules thereunder;

     (3)     do and perform any and all acts for and on behalf of the
             undersigned that may be necessary or desirable to complete and
             execute any such Form 3, 4, or 5 or Schedule 13D or 13G, complete
             and execute any amendment or amendments thereto, and timely file
             such form with the SEC and any stock exchange or similar authority;
             and

     (4)     take any other action of any type whatsoever in connection with the
             foregoing that, in the opinion of each such attorney-in-fact, may
             be of benefit to, in the best interest of, or legally required by,
             the undersigned, it being understood that the documents executed by
             each such attorney-in-fact on behalf of the undersigned pursuant to
             this Power of Attorney shall be in such form and shall contain such
             terms and conditions as each such attorney-in-fact may approve in
             each such attorney-in-fact's discretion.

     The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that each such
attorney-in-fact, or each such attorney-in-fact's substitute or substitutes,
shall lawfully do or cause to be done by virtue of this power of attorney and
the rights and powers herein granted. The undersigned acknowledges that each
foregoing attorney-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934, as amended.

     This Power of Attorney shall remain in full force and effect until
the undersigned is no longer required to file Forms 3, 4, 5, and any Schedules
13D or 13G with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the undersigned in a
signed writing delivered to each foregoing attorney-in-fact.

                  [Remainder of page intentionally left blank]

     IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of this 29 day of October, 2020


                                             /s/ Steven F. Bellon
                                             -----------------------------------
                                             Name: Steven F. Bellon, Ph.D.